Chances GlaxoSmithKline PLC can turn the tables on rival Merck & Co. Inc. with its vaccine against varicella zoster, the virus that causes shingles, were strengthened by confirmation GSK’s Shingrix achieved high efficacy in adults aged 70 years and over in a pivotal Phase III trial.
Results from its Phase III ZOE-70 trial assessing its shingles vaccine candidate in adults aged 70 and over were published...
Welcome to Scrip
Create an account to read this article
Already a subscriber?